Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs BIO-TECHNE Corp (TECH) Price & Performance

Dicks Sporting Goods IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs BIO-TECHNE Corp — how do they compare? Dicks Sporting Goods Inc trades at $205.25 (market cap $19.16B), while BIO-TECHNE Corp trades at $72.14 (market cap $11.24B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays the higher dividend (2.34%). Which is the better fit depends on your goals.

DKSTECH
Market Cap
$19.16B$11.24B
Sector
Consumer CyclicalHealth
52-Week High
$239.17$72.29
52-Week Low
$187.78$43.31
Enterprise Value
$25.95B$11.32B
Dividend Yield
2.34%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.

The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH